Michael A. Metzger - 13 Dec 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
13 Dec 2021
Net transactions value
-$462,276
Form type
4
Filing time
15 Dec 2021, 16:35:28 UTC
Previous filing
27 Oct 2021
Next filing
20 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $14,724 +2,045 +12% $7.20 19,704 13 Dec 2021 Direct
transaction SNDX Common Stock Sale $38,964 -2,045 -10% $19.05 17,659 13 Dec 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $220,518 +34,564 +196% $6.38 52,223 13 Dec 2021 Direct
transaction SNDX Common Stock Sale $658,555 -34,564 -66% $19.05 17,659 13 Dec 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -2,045 -100% $0.000000* 0 13 Dec 2021 Common Stock 2,045 $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -34,564 -100% $0.000000* 0 13 Dec 2021 Common Stock 34,564 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $19.00 to $19.49.
F3 This option is fully vested.